Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics (Nasdaq: ALGS) entered an exclusive license with Xiamen Amoytop to develop and commercialize pevifoscorvir sodium in Greater China for chronic HBV. Aligos will receive a $25M upfront, up to $420M in milestones, plus tiered high single-digit royalties.
Amoytop will fund development in the region; Aligos retains rights outside Greater China and expects current cash runway to extend into Q4 2026.
Aligos Therapeutics (Nasdaq: ALGS) reported first interim Phase 2 B-SUPREME results and FDA Fast Track Designation for pevifoscorvir sodium in chronic hepatitis B.
The DSMB recommended increasing the HBeAg- cohort sample size from 74 to 100, futility criteria were not met, study drugs were well tolerated, and topline data remain on track for 2027.
Aligos Therapeutics (Nasdaq: ALGS) reported Q4 and full-year 2025 business progress and financials on March 5, 2026. Key clinical milestones include completion of planned enrollment for 60 HBeAg- participants in the Phase 2 B-SUPREME study and continued HBeAg+ enrollment; topline data expected in 2027. ALG-170675 advanced into IND-enabling studies with partner Amoytop. Cash, cash equivalents and investments were $77.8M at Dec 31, 2025, providing runway into Q3 2026. Net loss narrowed to $24.2M for FY2025.
Aligos Therapeutics (Nasdaq: ALGS) will report its fourth quarter 2025 financial results on Thursday, March 5, 2026 before the open of U.S. markets.
The company is a clinical-stage biotechnology firm focused on therapies for liver and viral diseases; timing and format details for the release were announced on Feb. 26, 2026.
Aligos Therapeutics (Nasdaq: ALGS) reported positive clinical data presented at CROI (Feb 22–25, 2026) from two posters: a Phase 1 monotherapy study of pevifoscorvir sodium showing high viral suppression in chronic HBV, and pharmacokinetics data for ALG-097558 in hepatic and renal impairment.
The ALG-097558 work acknowledges partial federal funding under Contract No. 75N93023C00052 and presentations were scheduled Feb 23 and Feb 25, 2026 in Denver.
Aligos Therapeutics (Nasdaq: ALGS) announced inducement equity grants on Jan 29, 2026, awarding non-qualified stock options for an aggregate of 81,100 shares to newly hired employees under its 2024 Inducement Plan.
The options’ exercise price equals the closing market price on the grant date. Vesting: 25% at the first anniversary, then monthly over three additional years, subject to continued employment.
Aligos Therapeutics (Nasdaq: ALGS) provided a Phase 2 B-SUPREME study update for pevifoscorvir sodium in chronic HBV. The study has 144 subjects enrolled worldwide and remains on track to complete enrollment with topline data expected in 2027. The first protocol‑defined interim analysis (≈36 HBeAg‑ participants completing 12 weeks) is expected in 1H 2026; the second interim (≈55 HBeAg+ participants completing 24 weeks) is expected in 2H 2026. The company will remain blinded and rely on the Data Safety Monitoring Board for protocol assessments, including potential sample size re‑estimation. The company also announced the resignation of its EVP/CMO and has initiated a formal search for a successor.
Aligos (Nasdaq: ALGS) appointed James Hassard, MBA as Executive Vice President, Chief Commercial Officer effective January 13, 2026. Mr. Hassard will build and lead Aligos' global commercial capabilities and join the senior leadership team as the company plans for late‑stage development of pevifoscorvir sodium while progressing the Phase 2 B‑SUPREME study. He previously served as chief commercial officer at Crinetics and Arrowhead and held roles at Coherus Oncology, Amgen and Merck, with global experience in the US, Canada and Europe. Hassard holds a BSc in Pharmacology (University of Toronto) and an MBA (Nova Southeastern University).
Aligos Therapeutics (Nasdaq: ALGS) announced that its Compensation Committee granted non-qualified stock options to purchase an aggregate of 14,100 shares as inducement awards to newly hired employees on Dec 9, 2025. The awards were granted under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price equal to the closing price of Aligos common stock on the grant date and vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly, subject to continued employment.
Aligos Therapeutics (Nasdaq: ALGS) presented positive data at HEP-DART 2025 (Dec 7–11, 2025). Oral presentations covered 96-week and post-treatment follow-up data from a Phase 1 pevifoscorvir sodium monotherapy study in chronic HBV and new in vivo ALG-055009 data showing synergistic weight and fat-mass loss when combined with incretin receptor agonists.
In diet-induced obese mice, semaglutide (SEMA) produced a maximum 23.9% weight loss vs 33% for SEMA+ALG-055009 (additional 8.6%); tirzepatide (TIRZEP) monotherapy reached 27.1%–34.4% vs 39%–40% for TIRZEP+ALG-055009 (additional 5.8%–11.7%). Presentations also included early HBV and HDV ASO program posters.